Zoetis Inc. (NYSE:ZTS) Shares Sold by InTrack Investment Management Inc

InTrack Investment Management Inc lowered its stake in Zoetis Inc. (NYSE:ZTS) by 2.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,817 shares of the company’s stock after selling 135 shares during the period. InTrack Investment Management Inc’s holdings in Zoetis were worth $941,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Webster Bank N. A. boosted its stake in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares during the last quarter. Neo Ivy Capital Management acquired a new stake in Zoetis during the 4th quarter worth approximately $40,000. Quarry LP increased its position in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC acquired a new position in shares of Zoetis during the first quarter worth about $43,000. Finally, Ables Iannone Moore & Associates Inc. purchased a new position in Zoetis in the 4th quarter worth approximately $51,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.1 %

Shares of NYSE ZTS opened at $190.08 on Friday. The firm has a market cap of $86.12 billion, a PE ratio of 37.20, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a 50 day simple moving average of $188.07 and a 200 day simple moving average of $176.20. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.41 EPS. On average, research analysts forecast that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.91%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 33.86%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ZTS shares. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday. Stifel Nicolaus lifted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Finally, Piper Sandler boosted their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.